Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by Xponance Inc.

Xponance Inc. grew its position in Exact Sciences Co. (NASDAQ:EXAS) by 10.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,013 shares of the medical research company’s stock after buying an additional 2,264 shares during the quarter. Xponance Inc.’s holdings in Exact Sciences were worth $1,349,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. Perigon Wealth Management LLC boosted its holdings in Exact Sciences by 3.2% in the fourth quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company’s stock valued at $474,000 after purchasing an additional 264 shares during the period. Sanctuary Advisors LLC boosted its holdings in Exact Sciences by 2.0% in the fourth quarter. Sanctuary Advisors LLC now owns 13,625 shares of the medical research company’s stock valued at $763,000 after purchasing an additional 269 shares during the period. Daiwa Securities Group Inc. boosted its holdings in Exact Sciences by 2.1% in the fourth quarter. Daiwa Securities Group Inc. now owns 14,447 shares of the medical research company’s stock valued at $812,000 after purchasing an additional 300 shares during the period. Advisors Asset Management Inc. boosted its holdings in Exact Sciences by 1.4% in the third quarter. Advisors Asset Management Inc. now owns 28,650 shares of the medical research company’s stock valued at $1,952,000 after purchasing an additional 402 shares during the period. Finally, Intech Investment Management LLC boosted its holdings in Exact Sciences by 3.5% in the third quarter. Intech Investment Management LLC now owns 11,986 shares of the medical research company’s stock valued at $816,000 after purchasing an additional 402 shares during the period. 88.82% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

EXAS has been the subject of a number of recent research reports. Piper Sandler decreased their target price on Exact Sciences from $75.00 to $70.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Royal Bank of Canada initiated coverage on Exact Sciences in a report on Thursday, March 13th. They issued a “sector perform” rating and a $52.00 target price for the company. Barclays decreased their target price on Exact Sciences from $70.00 to $65.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. Benchmark reaffirmed a “buy” rating and set a $65.00 price target on shares of Exact Sciences in a report on Monday, January 13th. Finally, BTIG Research lifted their price target on Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Two equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $70.83.

Exact Sciences Stock Up 3.0 %

EXAS opened at $45.62 on Friday. The stock has a market capitalization of $8.47 billion, a P/E ratio of -8.19 and a beta of 1.25. Exact Sciences Co. has a one year low of $40.62 and a one year high of $79.62. The business’s 50-day simple moving average is $50.55 and its 200-day simple moving average is $58.27. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.23. The firm had revenue of $713.42 million for the quarter, compared to analysts’ expectations of $701.45 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. Analysts anticipate that Exact Sciences Co. will post -0.58 EPS for the current year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.